AMRX · Amneal Pharmaceuticals, Inc.

Track AMRX — free

$20.14 -0.06 (-0.30%)

S&P 600 member Russell 2000 member Rebalance outlook locked

Market Cap

$6.55B

319.35M

Volume · Sep 30 4.11M Avg daily vol (3M) 2.07M

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 4 wks

Latest filing: 10-Q

filed Aug 6, 2026

Q2 2026 earnings call transcript

call held Jul 30, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$3.12B

Trailing 12 months

Net income (TTM)

$157.36M

Trailing 12 months

Revenue growth YoY

+9.9%

Year over year

Operating margin

14.6%

Trailing 12 months

P / E (TTM)

42.1

Trailing earnings · reciprocal yield 2.4%

FCF yield

2.0%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

−$2.44B

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+1.8%

Year over year · more shares

Price change (1Y)

+104.7%

Trailing year

Short interest

3.5%

Latest settlement · 6.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026

Q2 FY26

TL;DR. Amneal delivered Q2 revenue of $796 million (+10%), adjusted EBITDA of $206 million (+12%), and adjusted EPS of $0.30 (+20%), and raised 2026 guidance for revenue, adjusted EBITDA and adjusted EPS while successfully repricing its Term Loan B to lower interest costs, though a flood at an India facility is expected to dent results and AvKARE revenue declined.

Bullish

+ Specialty segment revenue grew 17% driven by Crexont, Brekiya and Unithroid
+ Affordable Medicines revenue grew 13% on complex portfolio strength and new launches
+ Adjusted gross margin expanded 60 bps to 46.2% on favorable mix and efficiencies
+ Successful Term Loan B repricing cuts interest rate by 50 bps and saves ~$12 million annually

Bearish

− AvKARE revenue declined 4% due to weakness in low-margin distribution
− Severe flooding at India facility expected to cost ~$20 million in negative impact
− Acquisition costs of $7.6 million in Q2 related to pending Kashiv deal
− Legal-related charges of $8.1 million in Q2 tied to antitrust class action litigation

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Strong Buy Momentum Very Strong Sentiment Bearish Fundamentals Strong Quant / Vol High

Market backdrop VIX 16 · calm Equity put/call 0.38

Technical

price trend

Strong Buy

50 / 200-day cross No cross

Price vs 200-day avg +36%

above

Price vs 50-day avg +11%

above

RSI (14) 65

neutral

MACD trend Positive

52-week position 97%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +16%

trailing

6-month return +59%

trailing

YTD return +60%

this year

Relative strength +46%

vs S&P · 6-mo

Sentiment

smart money

Bearish

Trend (MA cross) No cross

50d $18 › 200d $15 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +48 funds added

Insider flow Distributing

Net -$7.2M over 90 days · 100% sells

Short interest Rising

3.54% of float · ▲ +6.8% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

312 holders — near 3-yr high, broad support

Squeeze score 64

elevated · 0–100

Fundamentals

Strong

Revenue growth +8%

Y/Y

Gross margin 37%

expanding

EPS growth +158%

Y/Y

Free cash flow $269.9M

Valuation P/E 42.7

rich

Balance sheet $2.3B

net debt

Quant / Vol

risk profile

High

Volatility 36%

annualized · 1-yr

Max drawdown −22%

past year

ATR 4.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 4 of last 6

Latest guidance · from the 8-K filed Jul 30, 2026

Net revenue · full year 2026 Initiated $3.1B – $3.2B

prior FY $3.02B midpoint +4.3% Y/Y

Adjusted EBITDA · full year 2026 Non-GAAP Initiated $750M – $780M

Adjusted diluted EPS · full year 2026 Non-GAAP Initiated $0.96 – $1.06

Operating cash flow · full year 2026 Initiated $350M – $400M

Operating cash flow, excluding discrete items · full year 2026 Initiated $375M – $425M

Guided vs delivered · last 6 settled

Net revenue full year 2024

guided $2.7B – $2.8B

guided $2.7B – $2.8B $2.79B In line

Net revenue 2023 Full Year

guided $2.37B – $2.42B

guided $2.37B – $2.42B $2.39B In line

Total company net revenue 2022

guided $2.15B – $2.25B

guided $2.15B – $2.25B $2.21B In line

Revenues Q1 2022

guided $500M

guided $500M $497.63M Miss −0.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+36% Bullish

Price vs 50-day avg

+11% Bullish

RSI (14)

65 Neutral

MACD trend

Positive Bullish

52-week position

97% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 3 of 6

Trend (MA cross) No cross

50d $18 › 200d $15 — 50d above 200d

Institutional flow Distributing

-2% holders QoQ · +48 funds added

Insider flow Distributing

Net -$7.2M over 90 days · 100% sells

Short interest Rising

3.54% of float · ▲ +6.8% MoM · 6.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

312 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $10 Now $20 · 97% Range high $21

vs 200-day avg +36% vs 50-day avg +11%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
AMRX Amneal Pharmaceuticals, Inc. this stock	$6.55B	+60.3%	+8.0%	42.7	3.5%
TAK Takeda Pharmaceutical Co Ltd	$60.23B	+18.7%	—	—	0.1%
GALDY Galderma Group AG/ADR	$46.00B	-3.8%	—	—	0.0%
TEVA Teva Pharmaceutical Industries Ltd	$45.67B	+27.6%	+4.3%	64.3	2.7%
HLN Haleon plc	$40.72B	-10.3%	—	—	0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

312

% held: 51.2%
Net QoQ: +2.4M sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

304

View

Short & Settlement

Short Interest Rising

Shares short

11.3M

Days to cover: 6.6d
Change: +717.9K sh

View

Short Volume

Short vol %

65%

As of: Sep 30, 2026

Short Total

View

Fails to Deliver

FTD shares

90.2K

Value: $1.6M
As of: Sep 8, 2026

View

Off-Exchange

Off-exchange %

48.3%

Week of: Aug 24, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$7.2M

Buyers / Sellers: 0 / 3

Buyers Sellers

View

Financials

Revenue (FY)

$3.0B

Net income (FY): $72.1M
EPS diluted: $0.22

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 10, 2026
This year: 17

View

Proposed Sales

Value

$2.9M

Shares: 168.6K
Filed: Aug 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Jul 30, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
AMRX	+3.6%	+15.6%	+58.9%	+15.6%	+60.3%
SPY	-1.2%	-0.4%	+13.1%	-0.4%	+12.1%
vs SPY	+4.8%	+16.0%	+45.9%	+16.0%	+48.3%

Key facts CIK 1723128 CUSIP 03168L105 13F (30d) 14 filings 10 filers Visit website Investor relations

AMRX · Amneal Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance